It's really hard to find the right residency positions nowadays. With MedResidency, you can easily find the best position for you. You don't have to look anywhere else because this website has all the resources you need. There are 62 vacancies added in the last 30 days so you can always find the opportunity.
Don't need to look anywhere else when searching for residency and fellowship positions. With MedResidency, vacancies are added every month so there's always position for you. There are also 8 institutions that post openings exclusively to their members so you can have the best chance of getting a position as soon as possible
Dr Nikhil Agnihotri after completing his post-graduation in General Surgery joined the prestigious Sir Ganga Ram Hospital New Delhi for post-doctoral fellowship in Minimal Access Surgery.
Academically proficient, he trains young laparoscopic surgeons across the globe and is also a peer reviewer for many national and international surgical journals.Dr Nikhil Agnihotri is currently the Director and Head, Department of Minimal Access, Metabolic and Bariatric Surgery at Max Super-specialty Hospital, Shalimar Bagh and Max Multispecialty Hospital, Pitampura New Delhi.Source: https://insightscare.com/burden-obesity-india/
Pharmacogenomics is the study of the relationship between genes and the drug response in humans.
The pharmacogenomics market is driven by significant growth in the pharmaceutical sector.
According to The European Federation of Pharmaceutical Industries and Associations’ Key Data 2019, the pharmaceutical sector in Europe was valued at US$ 139, 287 million in 2000, which increased to US$ 284, 028 million (est.)
According to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S. Pharmacogenomics has been greatly beneficial to clinical pharmacology by enabling pharmacists to customize treatment plans for patients with specific deficiencies or risks that would not have been treatable without this knowledge.
In April 2021, Vertex received European Commission label extension approval for triple combination cystic fibrosis treatment Kaftrio, extending its use for the ‘majority of patients aged 12 years and older in the U.K, Germany, and other European nations.
The field of pharmacogenomics now encompasses many types of research and studies.